OncoGenex Pharmaceuticals (OGXI) : The consensus on OncoGenex Pharmaceuticals (OGXI) based on 1 analyst recommendation on the company stock is 1, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 1 brokers have a differing view as they consider the stock to be a Strong Buy at current levels.
OncoGenex Pharmaceuticals (OGXI) : The highest level OncoGenex Pharmaceuticals (OGXI) is projected to reach is $4 for the short term and the lowest estimate is at $3. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $3.5 and the possibility the share price can swing is $0.71.
OncoGenex Pharmaceuticals (NASDAQ:OGXI): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.02 and $0.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.03. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.02, notching a gain of 0.99% for the day. The total traded volume was 96,687 . The stock had closed at $1.01 on the previous day.
The company shares have dropped -50.49% from its 1 Year high price. On Jul 28, 2015, the shares registered one year high at $4.10 and the one year low was seen on Jan 21, 2016. The 50-Day Moving Average price is $1.02 and the 200 Day Moving Average price is recorded at $0.87.
OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of new therapies that address treatment resistance in cancer patients. The Company has three product candidates in its pipeline: custirsen, apatorsen and OGX-225. Of the product candidates in its pipeline, custirsen and apatorsen are clinical-stage assets being evaluated in two Phase III studies and five Phase II studies. These product candidates focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote treatment resistance and survival of tumor cells and are over-produced in response to a variety of cancer treatments.